A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Abstract

Background: The combined use of anti-programmed cell death protein 1 (PD-1)/anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and nivolumab in ultra-rare cancers, including small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The purpose of the study was to evaluate the potential clinical benefit of ipilimumab and nivolumab in patients with SCCOHT.

Methods: DART was a prospective, open-labeled, multicenter (>1,000 US sites), multi-cohort phase II clinical trial of intravenous administration of ipilimumab (1 mg/kg, every 6 weeks) plus nivolumab (240 mg, every 2 weeks). The primary endpoint was overall response rate [ORR, confirmed complete response (CR) and partial response (PR)] per RECIST. Secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease ≥6 months), and toxicity. Immune responses were also evaluated.

Results: Six patients (median age, 30.5 years; median, 2 prior therapies; no prior immunotherapy exposure) with advanced/metastatic SCCOHT were evaluable. ORR and CBR were both 16.7% (1/6) with one patient having a confirmed CR lasting 46.2+ months. However, another patient had a confirmed immune CR (iCR) with immune PFS (iPFS) of 53+ months [ORR/iORR, 33.3% (2/6)]. Notably, the latter patient had a progressing lesion at 24 weeks after initial response, but with renewed regression with ongoing therapy, suggesting delayed pseudo-progression. At 12-months, 3 patients remained alive. Median PFS was 1.4 months (range, 0.9 months-not reached); median OS was 14.2 months (2 months-not reached). No adverse events caused treatment discontinuation.

Conclusion: Two of 6 patients (33.3%) with SCCOHT achieved durable CR/iCR and long-term survival with ipilimumab plus nivolumab. Correlative studies to determine response and resistance markers are ongoing.

Keywords

DART / ipilimumab / nivolumab / rare tumors / S1609 / small cell carcinoma of the ovary hypercalcemic type

References

[1] Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994; 18(11): 1102–16. https://doi.org/10.1097/00000478-199411000-00004

[2] Young RH, Goodman A, Penson RT, Russell AH, Uppot RN, Tambouret RH. Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass. N Engl J Med. 2010; 362(11): 1031–40. https://doi.org/10.1056/NEJMcpc1000272

[3] Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014; 46(5): 424–6. https://doi.org/10.1038/ng.2922

[4] Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WPD, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014; 46(5): 427–9. https://doi.org/10.1038/ng.2928

[5] Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014; 46(5): 438–43. https://doi.org/10.1038/ng.2931

[6] Karnezis AN, Wang Y, Ramos P, Hendricks WPd, Oliva E, D'Angelo E, et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016; 238(3): 389–400. https://doi.org/10.1002/path.4633

[7] Reed NS, Pautier P, Åvall-Lundqvist E, Ledermann JA, Colombo N, du Bois A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2014; 24(9 Suppl 3): S30–4. https://doi.org/10.1097/IGC.0000000000000293

[8] Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, et al. Small Cell Carcinoma of the Ovary, Hypercalcaemic Type – genetics, new treatment targets and current management guidelines. Clin Cancer Res Off J Am Assoc Cancer Res. 2020; 26(15): 3908–17. https://doi.org/10.1158/1078-0432.CCR-19-3797

[9] Witkowski L, Goudie C, Ramos P, Boshari T, Brunet J-S, Karnezis AN, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2016; 141(3): 454–60. https://doi.org/10.1016/j.ygyno.2016.03.013

[10] Pautier P, Ribrag V, Duvillard P, Rey A, Elghissassi I, Sillet-Bach I, et al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol Off J Eur Soc Med Oncol. 2007; 18(12): 1985–9. https://doi.org/10.1093/annonc/mdm376

[11] Callegaro-Filho D, Gershenson D, Nick A, Munsell MF, Ramirez PT, Eifel PJ, et al. Small Cell Carcinoma of the Ovary – Hypercalcemic Type (SCCOHT): A Review of 47 Cases. Gynecol Oncol. 2016; 140(1): 53–7. https://doi.org/10.1016/j.ygyno.2015.11.004

[12] Estel R, Hackethal A, Kalder M, Münstedt K. Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature. Arch Gynecol Obstet. 2011; 284(5): 1277–82. https://doi.org/10.1007/s00404-011-1846-5

[13] Jamy O, Yaghmour G, Hare F, Martin MG. Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary. Anticancer Res. 2015; 35(5): 3091–5.

[14] Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2017; 242(3): 371–83. https://doi.org/10.1002/path.4912

[15] Chan-Penebre E, Armstrong K, Drew A, Grassian AR, Feldman I, Knutson SK, et al. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models. Mol Cancer Ther. 2017; 16(5): 850–60. https://doi.org/10.1158/1535-7163.MCT-16-0678

[16] Soldi R, Weston A, Thode T, Lewis R, Kaadige M, Vankayalapati H, et al. Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT). Cancer Res. 2019; 79(13_Supplement): 3869. https://doi.org/10.1158/1538-7445.AM2019-3869

[17] Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, et al. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun. 2021; 12(1): 4319. https://doi.org/10.1038/s41467-021-24618-3

[18] Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, et al. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Mol Cancer Ther. 2018; 17(12): 2767–79. https://doi.org/10.1158/1535-7163.MCT-18-0348

[19] Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, et al. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. Cancer Res. 2019; 79(10): 2761–74. https://doi.org/10.1158/0008-5472.CAN-18-1545

[20] Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat Commun. 2019; 10(1): 558. https://doi.org/10.1038/s41467-018-06958-9

[21] Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, et al. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2018; 24(8): 1932–43. https://doi.org/10.1158/1078-0432.CCR-17-1928

[22] Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. Mol Cancer Ther. 2021; 20(12): 2341–51. https://doi.org/10.1158/1535-7163.MCT-21-0433

[23] Krishnamurthy N, Kato S, Lippman S, Kurzrock R. Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy. J Immunother Cancer. 2022; 10(9): e004669. https://doi.org/10.1136/jitc-2022-004669

[24] Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, et al. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. J Natl Cancer Inst. 2018; 110(7): 787–90. https://doi.org/10.1093/jnci/djx277

[25] Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021; 16: 223–49. https://doi.org/10.1146/annurev-pathol-042020-042741

[26] DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the United States. CA Cancer J Clin. 2017; 67(4): 261–72. https://doi.org/10.3322/caac.21400

[27] Board WC of TE. Female Genital Tumours. Accessed July 7, 2023. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020

[28] Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-We, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2019; 381(21): 2020–31. https://doi.org/10.1056/NEJMoa1910231

[29] Brookmeyer R, Crowley J. A k-Sample Median Test for Censored Data. J Am Stat Assoc. 1982; 77(378): 433–40. https://doi.org/10.2307/2287264

[30] Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021; 9(8): e002990. https://doi.org/10.1136/jitc-2021-002990

[31] Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, et al. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2020; 26(10): 2290–6. https://doi.org/10.1158/1078-0432.CCR-19-3356

[32] Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, et al. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021; 127(17): 3194–201. https://doi.org/10.1002/cncr.33591

[33] Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, et al. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res Off J Am Assoc Cancer Res. 2022; 28(2): 271–8. https://doi.org/10.1158/1078-0432.CCR-21-2182

[34] Patel SP, Othus M, Chae YK, Mace J, Yau C, Li L, et al. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia. Clin Cancer Res Off J Am Assoc Cancer Res. Published online October 26, 2023. https://doi.org/10.1158/1078-0432.CCR-23-2293

[35] Suyanto S, Yeo D, Khan S. A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. Case Rep Oncol Med. 2019; 2019: e8356148. https://doi.org/10.1155/2019/8356148

[36] Connor YD, Miao D, Lin DI, Dalrymple JL, Hacker MR, Shea M, et al. Elucidating the immune responsiveness of small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2020; 159: 130–1. https://doi.org/10.1016/j.ygyno.2020.05.162

[37] Lee EK, Esselen KM, Kolin DL, Lee LJ, Matulonis UA, Konstantinopoulos PA. Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. JCO Precis Oncol. 2020; 4: PO2000063. https://doi.org/10.1200/PO.20.00063

[38] Li G, Jiang Y. Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Front Oncol. 2022; 12: 916790. https://doi.org/10.3389/fonc.2022.916790

[39] Kolata G. Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong. The New York Times. https://www.nytimes.com/2018/02/19/health/ovarian-cancer-immunotherapy.html. Published February 19, 2018. Accessed March 18, 2023.

[40] Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015; 16(13): e498–509. https://doi.org/10.1016/S1470-2045(15)00007-8

[41] Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017; 18(7): 895–903. https://doi.org/10.1016/S1470-2045(17)30380-7

[42] Ratnayake G, Shanker M, Roberts K, Mason R, Hughes BGM, Lwin Z, et al. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia Pac J Clin Oncol. 2020; 16(1): 56–62. https://doi.org/10.1111/ajco.13242

[43] Ray-Coquard IL, Penel N, Bompas E, Levy C, Leary A, Bachelot T, et al. Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer. J Clin Oncol. 2022; 40(16_suppl): 5572. https://doi.org/10.1200/JCO.2022.40.16_suppl.5572

[44] Lin DI, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross JS, et al. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecol Oncol. 2017; 147(3): 626–33. https://doi.org/10.1016/j.ygyno.2017.09.031

[45] Auguste A, Blanc-Durand F, Deloger M, Le Formal A, Bareja R, Wilkes DC, et al. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis. Cells. 2020; 9(6): 1496. https://doi.org/10.3390/cells9061496

[46] Gamwell LF, Gambaro K, Merziotis M, Crane C, Arcand SL, Bourada V, et al. Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet J Rare Dis. 2013; 8: 33. https://doi.org/10.1186/1750-1172-8-33

[47] Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377): 801–6. https://doi.org/10.1126/science.aan5951

[48] Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, et al. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clin Cancer Res. 2020; 26(21): 5701–8. https://doi.org/10.1158/1078-0432.CCR-20-1825

[49] Naito T, Umemura S, Nakamura H, Zenke Y, Udagawa H, Kirita K, et al. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report. Thorac Cancer. 2019; 10(5): 1285–8. https://doi.org/10.1111/1759-7714.13070

[50] Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, et al. SWOG 1609 cohort 48: anti–CTLA-4 and anti–PD-1 for advanced gallbladder cancer. Cancer. 2024; 130(17): 2918–27. https://doi.org/10.1002/cncr.35243

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.